Cargando…
Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
Optimal management of systemic lupus erythematosus (SLE)‐associated pulmonary arterial hypertension (PAH) remains unclear. Our observation describes the case of a 31‐year‐old SLE patient presenting with cardiogenic shock revealing severe PAH, in which a therapeutic scheme combining immunosuppressant...
Autores principales: | Sanges, Sébastien, Savale, Laurent, Lamblin, Nicolas, Rémy‐Jardin, Martine, Humbert, Marc, Sobanski, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989275/ https://www.ncbi.nlm.nih.gov/pubmed/31536678 http://dx.doi.org/10.1002/ehf2.12507 |
Ejemplares similares
-
Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC/ERS definition of pulmonary hypertension and impact on mortality
por: Puigrenier, Sébastien, et al.
Publicado: (2022) -
Factors associated with the 6-minute walk distance in patients with systemic sclerosis
por: Sanges, Sébastien, et al.
Publicado: (2017) -
Relevance of Partitioning DLCO to Detect Pulmonary Hypertension in Systemic Sclerosis
por: Sivova, Nadia, et al.
Publicado: (2013) -
Pulmonary hypertension in systemic sclerosis: different phenotypes
por: Launay, David, et al.
Publicado: (2017) -
Systemic Lupus Erythematosus and Pulmonary Hypertension
por: Parperis, Konstantinos, et al.
Publicado: (2023)